The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 27, 2015
Filed:
Mar. 01, 2013
Hoffmann-la Roche Inc., Nutley, NJ (US);
Steven Joseph Berthel, Mendham Township, NJ (US);
Roland Joseph Billedeau, Santa Clara, CA (US);
Christine E. Brotherton-Pleiss, Sunnyvale, CA (US);
Fariborz Firooznia, Florham Park, NJ (US);
Stephen Deems Gabriel, Morristown, NJ (US);
Xiaochun Han, Cedar Grove, NJ (US);
Ramona Hilgenkamp, Montclair, NJ (US);
Saul Jaime-Figueroa, Morris Plains, NJ (US);
Buelent Kocer, Shanghai, CN;
Francisco Javier Lopez-Tapia, Honolulu, HI (US);
Yan Lou, Pleasanton, CA (US);
Lucja Orzechowski, Kinnelon, NJ (US);
Timothy D. Owens, San Carlos, CA (US);
Jenny Tan, New Providence, NJ (US);
Peter Michael Wovkulich, Nutley, NJ (US);
Hoffmann-La Roche Inc., Nutley, NJ (US);
Abstract
This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.